Saturn V Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Saturn V Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-368,176	Closed	-$17.1M	–	25
2025 Q3	$17.1M	Buy	368,176 +25,864	+8%	+$951K	3.76%	14
2025 Q2	$10M	Buy	+342,312	New	+$9.31M	4.07%	13

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Saturn V Capital Management's LENZ Position: Q4 2025 in Review

Saturn V Capital Management sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 368,176 shares — an estimated $17.1M sold.

Saturn V Capital Management first reported a position in LENZ in Q2 2025 and held it in 2 quarters. The position peaked at $17.1M in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

Saturn V Capital Management reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
Saturn V Capital Management sold 368,176 LENZ Therapeutics shares in Q4 2025, an estimated $17.1M.
Saturn V Capital Management first reported a position in LENZ Therapeutics in Q2 2025 and held it in 2 quarters.
Saturn V Capital Management's LENZ Therapeutics position peaked at $17.1M in Q3 2025.
160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Saturn V Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.